Nanocarriers for tuberculosis therapy: Design of safe and effective drug delivery strategies to overcome the therapeutic challenges

Sarkar, Kaushik; Kumar, Manoj; Jha, Abhishek; Bharti, Kanchan; Das, Mohana; Mishra, Brahmeshwar

doi:10.1016/j.jddst.2021.102850

Cited by 15 publications

(11 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, it is precisely the complexity of the therapy that impedes patient compliance, and ultimately favors the emergence of resistant strains. In general, antitubercular drugs have low solubility, low metabolic stability, and low tissue penetration [ 49 ]. The challenge is to achieve therapeutic concentrations at the site of infection.…”

Section: Tuberculosismentioning

confidence: 99%

“…Regarding TB, a review published in 2005 already stated the advantages of nanotechnologies compared to standard treatments: in particular, high stability for prolonged storage, high levels of encapsulation and loadings of active molecules, incorporation of hydrophilic molecules as well as hydrophobic ones, design for various routes of administration and controlled and the prolonged release of active substances [ 80 ]. Thus, over the last years, it has been shown that the various DDSs listed above are also applicable for the treatment of TB [ 1 , 2 , 49 , 81 , 82 ].…”

Section: Nanoparticlesmentioning

confidence: 99%

See 1 more Smart Citation

Nanosized Drug Delivery Systems to Fight Tuberculosis

2023

View full text Add to dashboard Cite

Tuberculosis (TB) is currently the second deadliest infectious disease. Existing antitubercular therapies are long, complex, and have severe side effects that result in low patient compliance. In this context, nanosized drug delivery systems (DDSs) have the potential to optimize the treatment’s efficiency while reducing its toxicity. Hundreds of publications illustrate the growing interest in this field. In this review, the main challenges related to the use of drug nanocarriers to fight TB are overviewed. Relevant publications regarding DDSs for the treatment of TB are classified according to the encapsulated drugs, from first-line to second-line drugs. The physicochemical and biological properties of the investigated formulations are listed. DDSs could simultaneously (i) optimize the therapy’s antibacterial effects; (ii) reduce the doses; (iii) reduce the posology; (iv) diminish the toxicity; and as a global result, (v) mitigate the emergence of resistant strains. Moreover, we highlight that host-directed therapy using nanoparticles (NPs) is a recent promising trend. Although the research on nanosized DDSs for TB treatment is expanding, clinical applications have yet to be developed. Most studies are only dedicated to the development of new formulations, without the in vivo proof of concept. In the near future, it is expected that NPs prepared by “green” scalable methods, with intrinsic antibacterial properties and capable of co-encapsulating synergistic drugs, may find applications to fight TB.

show abstract

Section: Tuberculosismentioning

confidence: 99%

Section: Nanoparticlesmentioning

confidence: 99%

Nanosized Drug Delivery Systems to Fight Tuberculosis

2023

View full text Add to dashboard Cite

show abstract

“…For thousands of years, Mtb still remains one of the most exceptional and intelligent bacterial pathogens on earth due to its numerous escape pathways from immunological clearance during its concurrent development with human beings [ 113 , 114 ]. One of the major challenges is to countercharge the immune escape of Mtb for medication-resistant TB or TB therapy.…”

Section: Selenium Nanoparticles For the Treatment Of Intracellular ...mentioning

confidence: 99%

Treatments of Mycobacterium tuberculosis and Toxoplasma gondii with Selenium Nanoparticles

Ifijen

Atoe²,

Ekun

et al. 2023

BioNanoSci.

View full text Add to dashboard Cite

Toxoplasma gondii and Mycobacterium tuberculosis are pathogens that are harmful to humans. When these diseases interact in humans, the result is typically fatal to the public health. Several investigations on the relationship between M. tuberculosis and T. gondii infections have found that there is a strong correlation between them with each infection having a reciprocal effect on the other. TB may contribute to the reactivation of innate toxoplasmosis or enhance susceptibility to a new infection, and toxoplasma co-infection may worsen the severity of pulmonary tuberculosis. As a consequence, there is an earnest and urgent necessity to generate novel therapeutics that can subdue these challenges. Selenium nanostructures’ compelling properties have been shown to be a successful treatment for Mycobacterium TB and Toxoplasma gondii. Despite the fact that selenium (Se) offers many health advantages for people, it also has a narrow therapeutic window; therefore, consuming too much of either inorganic or organic compounds based on selenium can be hazardous. Compared to both inorganic and organic Se, Se nanoparticles (SeNPs) are less hazardous. They are biocompatible and excellent in selectively targeting specific cells. As a consequence, this review conducted a summary of the efficacy of biogenic Se NPs in the treatment of tuberculosis (TB) and toxoplasmosis. Mycobacterium tuberculosis , Toxoplasma gondii , and their co-infection were all briefly described.

show abstract

“…Nanoparticle-mediated delivery of anti-tubercular drugs provides distinct advantages over free drug molecules, like prolonged circulation and enhanced access of the therapeutic payload to the Mycobacterial tuberculosis-infected cells and tissues, consequently increasing the efficacy of the therapy. In addition, prolonged release of the drugs from nanosized carriers ensures persistent therapeutic concentrations of the drug for a more extended period, along with a better pharmacokinetic profile ensuring a less frequent dosage regimen and lower dose requirement [ 204 ].…”

Section: Mesoporous Silica Nanoparticlesmentioning

confidence: 99%

Mesoporous silica nanocarriers as drug delivery systems for anti-tubercular agents: a review

2022

View full text Add to dashboard Cite

The treatment and management of tuberculosis using conventional drug delivery systems remain challenging due to the setbacks involved. The lengthy and costly treatment regime and patients' non-compliance have led to drug-resistant tuberculosis, which is more difficult to treat. Also, anti-tubercular drugs currently used are poor water-soluble drugs with low bioavailability and poor therapeutic efficiency except at higher doses which causes drug-related toxicity. Novel drug delivery carrier systems such as mesoporous silica nanoparticles (MSNs) have been identified as nanomedicines capable of addressing the challenges mentioned due to their biocompatibility. The review discusses the sol–gel synthesis and chemistry of MSNs as porous drug nanocarriers, surface functionalization techniques and the influence of their physico-chemical properties on drug solubility, loading and release kinetics. It outlines the physico-chemical characteristics of MSNs encapsulated with anti-tubercular drugs.

show abstract

Nanocarriers for tuberculosis therapy: Design of safe and effective drug delivery strategies to overcome the therapeutic challenges

Cited by 15 publications

References 71 publications

Nanosized Drug Delivery Systems to Fight Tuberculosis

Nanosized Drug Delivery Systems to Fight Tuberculosis

Treatments of Mycobacterium tuberculosis and Toxoplasma gondii with Selenium Nanoparticles

Mesoporous silica nanocarriers as drug delivery systems for anti-tubercular agents: a review

Contact Info

Product

Resources

About